NCT03770416View on ClinicalTrials.gov

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

February 10, 2025

Study Completion Date

February 10, 2025

Conditions

Central Nervous System B-Cell Non-Hodgkin LymphomaRecurrent Central Nervous System LymphomaRefractory Central Nervous System Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03770416 - Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma | Biotech Hunter | Biotech Hunter